tbuckley/cabot-search huggingface dataset:
Clinical Action against Drunk Driving
Authors: Donald A. Redelmeier, Allan S. Detsky
Journal: PLoS Medicine (2017)

In 2014, over 100,000 people in the United States were hospitalized because of alcohol-related traffic crashes, and 9,967 died (exceeding the 6,721 US deaths from HIV in the same year) [1,2].On 17 March 2017, the National Highway Traffic Safety Administration (NHTSA) plans to promote a safety campaign against drunk driving.Past estimates suggest that law enforcement against drunk driving reduces traffic fatalities by 20% and that high-probability detection is more effective than high-severity punishment [3,4].Yet, 12 states in the US, including the large states of Texas and Minnesota, prohibit random sobriety checkpoints, and the remaining have uneven efforts against drunk driving [5].This Perspective identifies some groups with a vested interest in preventing drunk driving, describes reasons for the relative inaction, and proposes more action by physicians.Traditionally, physicians and allied health care providers have deferred to others about how to address the health risks of drunk driving.One explanation is that drunk driving is a behavioral choice, and behavioral change is difficult to effect in a time-limited clinical encounter [6].Moreover, preventive care may provide less evident benefit to the patient than prescribing an acid blocker, for example, to treat symptomatic alcohol-induced gastritis.While a pregnant woman who drinks alcohol is likely to be warned by her obstetrician or midwife on the risks to fetal development, most patients in our experience who are prone to drunk driving are easily missed because physicians rarely ask about drunk driving, despite often asking about alcohol.As a consequence, standard care may fail to identify this prevalent, modifiable, and serious health risk.Vehicle manufacturers are the most powerful commercial group that can promote traffic safety.Over time, this industry has carefully developed and marketed technologies to protect drivers, such as seat belts, airbags, antilock brakes, and safety glass.Currently, the main technology to prevent drunk driving is an ignition interlock that forces drivers to have a breath test before engine engagement.This device, now imposed only on the vehicles of convicted drunk drivers, is unlikely to be adopted broadly any time soon unless manufacturers want to boast that they make the safest cars for those prone to drunk driving.The net result is that vehicle regulators in the US are unable to rely on manufacturer innovations or economic forces to prevent drunk driving.Other large groups have even less incentive to promote sobriety while driving.Alcohol manufacturers promote "responsible drinking," which is a vacuous tautology because adverse events can be deemed "irresponsible" by rhetorical hindsight.Celebrities in the entertainment industry are occasionally charged with drunk driving yet rarely express enduring regret.
Empathic communication for reduction of pain perception and anxiety in patients implanted central venous accesses for cancer therapy: an experience of 51 cases
Authors: N. Piccolo, S. Barni, S. Ambroso, L.C. Crocco, R. Giustina, E. Viterbo, F. Petrelli, G. Cavallari, G. Sgroi, K. Borgonovo, A. Varetto
Journal: Annals of Oncology (2016)
Incidence and Prognostic Value of FLT-3 and NPM1 Genes Abnormalities in Acute Myeloid Leukemia in the Côte D’or Population, France
Authors: Marc Maynadié, Martine Courtois, Morgane Mounier, Ines Janoray-Manivet, Ingrid Lafon, Julien Guy, Paule-Marie Carli, François Girodon
Journal: Blood (2008)
P19.03 Randomized double arm phase III study to evaluate feasibility and safety of Gamma Knife radiosurgery versus Linac Based (Edge) radiosurgery in brain metastatic patients
Authors: P. Navarria, A. Ascolese, L. Cozzi, S. Tomatis, P. Picozzi, G. Pecchioli, L. Attuati, E. Clerici, G. Maggi, M. Scorsetti
Journal: Neuro-Oncology (2016)
Safety of the natural killer (NK) cell-targeted anti-KIR antibody, lirilumab (liri), in combination with nivolumab (nivo) or ipilimumab (ipi) in two phase 1 studies in advanced refractory solid tumors
Authors: N.H. Segal, J.R. Infante, R.E. Sanborn, G.T. Gibney, D.P. Lawrence, N. Rizvi, R. Leidner, T.F. Gajewski, E. Bertino, W.H. Sharfman, S. Cooley, S.L. Topalian, W.J. Urba, J.D. Wolchok, X. Gu, C. Passey, D. McDonald, P. Aanur, S. Srivastava, F.S. Hodi
Journal: Annals of Oncology (2016)
Cell Guidance on Nanostructured Metal Based Surfaces
Authors: Yulia Zhukova, Ekaterina V. Skorb
Journal: Advanced Healthcare Materials (2017)

Metal surface nanostructuring to guide cell behavior is an attractive strategy to improve parts of medical implants, lab‐on‐a‐chip, soft robotics, self‐assembled microdevices, and bionic devices. Here, we discus important parameters, relevant trends, and specific examples of metal surface nanostructuring to guide cell behavior on metal‐based hybrid surfaces. Surface nanostructuring allows precise control of cell morphology, adhesion, internal organization, and function. Pre‐organized metal nanostructuring and dynamic stimuli‐responsive surfaces are used to study various cell behaviors. For cells dynamics control, the oscillating stimuli‐responsive layer‐by‐layer (LbL) polyelectrolyte assemblies are discussed to control drug delivery, coating thickness, and stiffness. LbL films can be switched “on demand” to change their thickness, stiffness, and permeability in the dynamic real‐time processes. Potential applications of metal‐based hybrids in biotechnology and selected examples are discussed.
Cardiotoxic effects of the novel anti-ErbB2 agent ado trastuzumab emtansine
Authors: R.V. Iaffaioli, C. Coppola, G. Piscopo, G. Riccio, A. Rienzo, C. Maurea, A. Barbieri, C. De Lorenzo, N. Maurea
Journal: Annals of Oncology (2016)
Gender differences in functional activity of the thyroid gland in C57BL/6 mice in dynamics of transplantable В16/F10 melanoma growth
Authors: L. Vladimirova, V. Bandovkina, E. Franciyans, O. Kit, N. Cheryarina, I. Kaplieva, E. Islamova, A. Salatova, L. Sergostyants, M. Cherkes
Journal: Annals of Oncology (2016)
Intergenic Variants of HBS1L-MYB Are Responsible for a Major Quantitative Trait Locus on Chromosome 6q23 Influencing HbF Levels in Adults.
Authors: Swee Lay Thein, Stephan Menzel, Xu Peng, Steve Best, Jie Jiang, James Close, Nicholas Silver, Ageliki Gerovasilli, Chen Ping, Masao Yamaguchi, Karin Wahlberg, Heike Muller, Tim D. Spector, Chad Garner, Fumihiko Matsuda, Martin Farrall, Mark Lathrop
Journal: Blood (2006)
Polymorphisms of DNA-repair genes associated with clinical outcome in metastatic breast cancer (MBC) patients treated with gemcitabine/cisplatin (GC) (California Cancer Consortium)
Authors: M. A. Gordon, W. Zhang, D. Yang, D. Spicer, J. Doroshow, K. Margolin, T. Synold, K. Albain, H. Chew, D. Gandara, H. J. Lenz
Journal: Journal of Clinical Oncology (2006)

675 Background: DNA repair enzymes may play an important role in determining efficacy of chemotherapy in MBC. In particular, GC combination therapy may be dependent on activity of DNA repair enzymes in host cells, since cisplatin acts by inducing DNA damage. Cancer cells with increased DNA repair capacity may be resistant to GC, and specific genes may be responsible for this increased repair capacity. We examined whether polymorphisms in genes related to DNA repair were associated with clinical outcome in MBC patients treated with GC, enrolled in a parent phase II clinical trial (Ph II-14 A &amp; B). Methods: Fifty-five patients with MBC were evaluated. Patients received the following regimen: 25 mg/m 2 cisplatin on days 1–4; 1000 mg/m 2 gemcitabine on days 2 and 8 of 21-day cycle. Thirteen polymorphisms in 10 cancer-related genes were tested for association with overall survival, time to tumor progression, and tumor response using a PCR RFLP based assay. Results: Of 55 patients evaluated, there were 17 responders (31%) and 33 non-responders (60%). Five patients (9%) inevaluable for response. Of 33 non-responders, 15 had stable disease, 18 had progressive disease. Median survival: 11.7 months with median follow-up 32.4 months for 4 patients alive at time of analysis. Median progression-free survival: 4.2 months. XPD Lys751Gln polymorphism was associated with overall survival and time to tumor progression (p=0.0003, p=0.006, respectively, log-rank test). Thirty-five patients carried Lys/Lys genotype, of which 29% resopnded. Fourteen patients carried Lys/Gln genotype, of which 54% resopnded. Five patients carried Gln/Gln genotype, with no responders. XRCC3 Thr241Met polymorphism was associated with time to tumor progression and tumor response (p=0.03, p=0.002, respectively). Eighteen patients had Met/Met genotype, of which 47% responded. Twenty-six patients had heterozygous genotype, of which 17% responded. Five patients had homozygous Thr/Thr, of which 100% responded. Conclusions: Our results suggest that polymorphisms in DNA repair genes XPD and XRCC3 may be important markers in predicting clinical outcome in MBC patients treated with GC. Supported by the following NCI grant: N01 CM1701. [Table: see text]
OS1.4 Current treatment regimens induce the mTORC1 inhibitor REDD1 in human glioblastoma cells: implications for treatment efficacy
Authors: M. Foltyn, A. Thiepold, P. N. Harter, P. Baumgarten, M. Mittelbronn, H. Urban, J. P. Steinbach, M. W. Ronellenfitsch
Journal: Neuro-Oncology (2016)
Prebiotic inulin-type fructans induce specific changes in the human gut microbiota
Authors: Doris Vandeputte, Gwen Falony, Sara Vieira-Silva, Jun Wang, Manuela Sailer, Stephan Theis, Kristin Verbeke, Jeroen Raes
Journal: Gut (2017)

Contrary to the long-standing prerequisite of inducing selective (ie, bifidogenic) effects, recent findings suggest that prebiotic interventions lead to ecosystem-wide microbiota shifts. Yet, a comprehensive characterisation of this process is still lacking. Here, we apply 16S rDNA microbiota profiling and matching (gas chromatography mass spectrometry) metabolomics to assess the consequences of inulin fermentation both on the composition of the colon bacterial ecosystem and faecal metabolites profiles.Faecal samples collected during a double-blind, randomised, cross-over intervention study set up to assess the effect of inulin consumption on stool frequency in healthy adults with mild constipation were analysed. Faecal microbiota composition and metabolite profiles were linked to the study's clinical outcome as well as to quality-of-life measurements recorded.While faecal metabolite profiles were not significantly altered by inulin consumption, our analyses did detect a modest effect on global microbiota composition and specific inulin-induced changes in relative abundances of Anaerostipes, Bilophila and Bifidobacterium were identified. The observed decrease in Bilophila abundances following inulin consumption was associated with both softer stools and a favourable change in constipation-specific quality-of-life measures.Ecosystem-wide analysis of the effect of a dietary intervention with prebiotic inulin-type fructans on the colon microbiota revealed that this effect is specifically associated with three genera, one of which (Bilophila) representing a promising novel target for mechanistic research.NCT02548247.
Establishment of a voluntary electronic Chlamydia trachomatis laboratory surveillance system in Germany, 2008 to 2014
Authors: Sandra Dudareva-Vizule, Karin Haar, Andrea Sailer, Klaus Jansen, Osamah Hamouda, Hilmar Wisplinghoff, Carsten Tiemann, Eberhard Pape, Viviane Bremer
Journal: Eurosurveillance (2017)

Chlamydia trachomatis (CT) infections are not reportable in Germany and limited data on prevalence are available. CT screening has been offered free of charge to pregnant women since 1995 and to all women under 25 years since 2008. For symptomatic women and men, diagnostic testing is covered by statutory health insurance. We describe the establishment of a nationwide, laboratory-based, voluntary sentinel that electronically collects information on all performed CT tests with test results, test reason and patient information. The sentinel represents one third of all performed CT tests in Germany. In the period from 2008 to 2014, 3,877,588 CT tests were reported, 93% in women. Women aged 20-24 years and men aged 25-29 years were the most frequently tested age groups. The overall proportion of positive tests (PPT) among women was 3.9% and among men 11.0%. The highest PPT among women was in the age groups 15-19 (6.8%) and 20-24 years (5.9%), and among men in the age groups 20-24 (19.2%), 15-19 (15.4%) and 25-29 years (14.8%). The PPT for CT was high among women and men younger than 25 years. Prevention is urgently needed. Monitoring of CT infection in Germany should be continued.
Clinicopathological characteristics and BRCA1/2 mutation rate in male breast cancer: a retrospective case series by the Hellenic Society of Medical Oncology
Authors: G. Lypas, D. Tryfonopoulos, E. Saloustros, P. Zacharopoulou, L. Florentin, A. Apessos, E. Kabletsas, E. Prinarakis, V. Barbounis, G. Fountzilas, D. Mavroudis, V. Georgoulias
Journal: Annals of Oncology (2016)
TMOD-25. MODELING ADULT PRONEURAL AND MESENCHYMAL GLIOBLASTOMA USING RCAS/T-VA TECHNOLOGY
Authors: Cameron Herting, Dolores Hambardzumyan
Journal: Neuro-Oncology (2016)

Glioblastoma (GBM) is the most common and aggressive malignant glioma, characterized by genetic heterogeneity, resistance to treatment, and dismal prognosis. The bulk of research in GBM biology utilizes passaged cell lines and xenograft models that may neglect some aspects of the tumor-stroma interactions, particularly the actions of the immune system. Additionally, the standard of care neglects the four subtypes that have been identified through analysis of the Cancer Genome Atlas. In order to advance exact research into GBM tumorigenesis, progression and treatment, we utilized RCAS/t-va technology to develop mouse models of adult proneural and mesenchymal GBM. The proneural GBM model was generated by overexpression of platelet-derived growth factor (PDGFB) in adult Ntv-a; Ink4a-Arf-/-;Ptenfl/fl mice. The mesenchymal GBM model was generated by co-injecting RCAS-shNf1, RCAS-shp53 and RCAS-Cre into sub ventricular zone of adult Ntv-a; Ink4a-Arf-/-;Ptenfl/fl mice. Both models display near to 100 % tumor formation. Comparison of these two models has demonstrated marked differences in the tumor microenvironment. Most notably, the mesenchymal subtype displays a significantly higher proportion of activated macrophage and microglia within the tumor as measured by immunohistochemical staining for macrophage markers Iba1 and CD68. Moreover, CD31 staining shows significantly higher vessel coverage and larger average vessel size in the proneural subtype. The data generated from our two models are similar to the data generated from analysis of human tissue samples, supporting their validity. Future analysis of these models will allow for the elucidation of additional molecular markers, gene expression and cellular characteristics that differ between the mesenchymal and proneural subtypes. This will allow for the development and accurate preclinical testing of subtype-specific targeted therapies.
Clinical and Virological Responses to Anti-Viral Treatment Correlates with Regulatory T-Cells Evolution in Patients with HCV-Induced Cryoglobulinemia Vasculitis.
Authors: Dan Avi Landau, Michelle Rosenzwajg, David Saadoun, Helene Trebeden-Negre, Patrice Cacoub, David Klatzmann
Journal: Blood (2007)
Drug-drug interactions between abiraterone (ABI) or enzalutamide (ENZ) and concomitant medications in patients with metastatic castration resistant prostate cancer (mCRPC)
Authors: E. Fantinel, R. Iacovelli, A. Modena, C. Ciccarese, D. Bimbatti, G. Tortora
Journal: Annals of Oncology (2016)
Alfred G. Knudson Jr, MD, PhD: In Memoriam (1922–2016)
Authors: Jonathan Chernoff
Journal: Cancer Research (2017)

![][1] 

One can hardly open an issue of Cancer Research without finding a half-dozen or more articles that address the role of various tumor suppressor genes in cancer. We now take it for granted that cancer is, at its core, a genetic disease and that one of the most important ways
QLIF-23. FUNCTIONAL OUTCOME, SYMPTOM BURDEN AND SURVIVAL VARY BY MOLECULAR SUBGROUP IN PATIENTS WITH ANAPLASTIC GLIOMA
Authors: Michelle Kim, Shawn Hervey-Jumper, Yebin Tao, Matthew Schipper, Daniel A. Orringer, Jason A. Heth, Larry Junck, Aaron Mammoser, Christopher Kim, Theodore Lawrence, Christina Tsien, Terri S. Armstrong
Journal: Neuro-Oncology (2016)

Given the distinct survival differences among molecular subgroups of anaplastic glioma, we investigated whether disease-associated function and symptom measures varied by subgroup and were associated with survival. Fifteen patients with grade III glioma treated on a phase I protocol of gemcitabine plus local-field radiation (RT, 60 Gy/30 fractions) without progression at 6 months post RT and available IDH1 and/or 1p/19q status were included in this retrospective study. MMSE, KPS, and EORTC QLC-30/BN20 disease-associated domains of cognitive and physical function, visual and motor dysfunction were compared between IDH1 (IDHm, n=10 vs IDHwt, n=3) and 1p/19q (codeleted, n=4 vs intact, n=8) subgroups using Fisher’s exact test, and associated with progression-free (PFS) and overall survival (OS) using Cox univariate analysis. Median age was 46 years (23-70), median pre-RT MMSE was 30 (24-30) and KPS 90 (70-100), with no significant baseline differences in these factors between subgroups. PFS and OS were higher in favorable (OS IDHm 72.1 months, codeleted inestimable) vs unfavorable subgroups (OS IDHwt 25.5 months, intact 72.1 months). Sixty percent (6/10) of IDHm patients retained stable self-reported cognitive function, and 3 (30%) had improved function whereas 2 (100%) of 2 IDHwt patients with available data improved at 6 months. Fifty percent (4/8) of 1p/19q intact patients had improved report of physical function vs 1 (25%) codeleted patient at 6 months. Although 1p/19q intact patients had worse visual and motor dysfunction at baseline, no significant difference between subgroups was seen at 6 months. Baseline and change in factors were not significantly associated with PFS or OS. In these pilot data, unfavorable molecular subgroups had worse survival and baseline neurologic dysfunction, but experienced significant recovery of physical and cognitive function after treatment. Whether tumor or patient-related factors account for this selective recovery will be explored in future studies.
Phase I/II CANON study: oncolytic immunotherapy for the treatment of non-muscle invasive bladder (NMIBC) cancer using intravesical coxsackievirus A21
Authors: H.S. Pandha, N. Annels, M. Arif, H. Mostafid, S. Sandhu, K. Harrington, A. Melcher, D. Mansfield, G. Au, M. Grose, R. Karpathy, D. Shafren
Journal: Annals of Oncology (2016)
Impact of age on the safety and efficacy of bevacizumab (BEV)-containing therapy in patients (pts) with primary ovarian cancer (OC): Analyses of the OTILIA German non-interventional study on behalf of the North-Eastern German Society of Gynaecological Oncology Ovarian Cancer Working Group
Authors: A. Mustea, P. Wimberger, G. Oskay-Oezcelik, P. Jungberg, W. Meinerz, D. Reichert, J. Janssen, M. Keller, R. Richter, J. Harde, S. Klawitter, A. Wegenaer, M. Mueller, J. Sehouli
Journal: Annals of Oncology (2016)
In Vitro Expanded MSCs From Patients with Myeloprliferative Neoplasms at Late Passages Show Recurrent Cytogenetic Abnormalities
Authors: Valentina Achille, Francesca Novara, Melissa Mantelli, Maria Antonietta Avanzini, Vittorio Rosti, Rita Maccario, Maria ester Bernardo, Franco Locatelli, Marco Zecca, Orsetta Zuffardi, Giovanni Barosi
Journal: Blood (2010)
GENT-25. hTERT PROMOTER HYPERMETHYLATION IS ASSOCIATED WITH INFAVOURABLE MOLECULAR SUBTYPES AND TELOMERASE RE-ACTIVATION IN PEDIATRIC EPENDYMOMA
Authors: Johannes Gojo, Daniela Lötsch, Kristian W. Pajtler, Lukas Chavez, Sabine Spiegl-Kreinecker, Katharina Neumayer, Pia Korbel, Asuka Araki, Thomas Mohr, Volker Hovestadt, Stefan M. Pfister, Thomas Czech, Martin Filipits, Marcel Kool, Andreas Peyrl, Irene Slavc, Walter Berger, Christine Haberler
Journal: Neuro-Oncology (2016)

Recent high-throughput analyses have brought forward novel molecular subgroups of ependymoma, one of the most frequent pediatric brain tumors. However, the mechanisms underlying the distinct behaviour of these subtypes are no entirely clear. The ribonucleotide enzyme telomerase (hTERT), which is capable of elongating shortened telomeres, has been associated with an aggressive course of ependymoma. Herein, we evaluated hTERT promoter methylation patterns, promoter mutation and the rs2853699 within the hTERT promoter as potential mechanisms of telomerase re-activation across different ependymoma subgroups. hTERT promoter mutations were not present in all samples analyzed and levels of telomerase activity and hTERT mRNA expression did not differ among rs2853699 alleles (n=29). Interestingly, no homozygous C allele was observed in ST-EPN-RELA tumors, which might be connected to the disruption of a RelA binding site in this genotype. hTERT promoter methylation tested by pyrosequencing in a promoter region upstream of the rs2853699 was significantly elevated in both posterior fossa and supratentorial ependymomas, the latter showing the highest methylation levels (n=68). Furthermore, hTERT promoter-methylation was significantly associated with higher telomerase activity and Ki67 index but not hTERT mRNA expression. For detailed analysis across molecular ependymoma subgroups, methylation patterns of three additional CpG sites within the hTERT promoter were analyzed in an independent Illumina 450K methylation array dataset (GSE65362, n=500). The CpG site located closest to the transcription start site was hypomethylated in all ependymoma subgroups. In contrast, the more distal sites were almost exclusively hypermethylated in PF-EPN-A and ST-EPN-RELA subtypes. Whereas all ST-EPN-RELA tumors showed hypermethylation, the pattern was more heterogeneous within the PF-EPN-A subgroup. Therefore, we tested the impact of hTERT promoter hypermethylation on survival probabilities within the PF-EPN-A subgroup (n=17), but no significant effect could be determined. Taken together, we present hTERT promoter hypermethylation as potential subgroup-specific mechanism for telomerase re-activation in pediatric ependymoma.